Are Amarin's Blockbuster Dreams Over?

When the U.S. Food and Drug Administration approved a widened use for Amarin's (NASDAQ:AMRN) cardiovascular drug Vascepa in December, hopes were high that it could turn into a blockbuster. However, a court ruling may have burst that bubble this week. Amarin shares sank 70% after a federal judge invalidated several patents pertaining to the drug. That means generic competitors may enter the market and take a piece of the pie sooner rather than late